Bioconvergence market seen reaching $263.67 billion by 2030
The Bioconvergence Global Market Report 2026 from The Business Research Company says the market rose to $175.26 billion in 2026 and is projected to hit $263.67 billion by 2030. Growth is being driven by personalized medicine, AI in life sciences and broader cross-industry collaboration, with North America leading now and Asia-Pacific set to grow fastest.
Why it matters: - Bioconvergence is moving biology deeper into engineering, data science and advanced technology, which is reshaping healthcare, biotechnology and life sciences. - The market’s growth points to rising demand for precision medicine, advanced diagnostics and bioengineered products. - Faster development of therapies, devices and platforms could lower costs and improve patient outcomes.
What happened: - The Business Research Company published the Bioconvergence Global Market Report 2026, covering market size, trends and a forecast through 2030. - The report says the bioconvergence market grew from $158.2 billion in 2025 to $175.26 billion in 2026. - The report projects the market will reach $263.67 billion by 2030. - The report pegs the historical and forecast CAGR at 10.8%. - The report says North America held the largest market share in 2025. - The report says Asia-Pacific is expected to be the fastest-growing region during the forecast period.
The details: - The market’s recent growth has been fueled by genomics research, wider adoption of digital health tools, increased biotechnology funding, stronger demand for sophisticated diagnostics and more interdisciplinary collaboration. - Future growth is expected to come from personalized medicine, AI-driven life sciences, bioengineering advances, data-centric healthcare and cross-industry partnerships. - The report highlights several trends, including the combination of biological sciences with engineering systems, expansion of precision medicine platforms, broader use of AI-driven drug discovery, greater use of bioinformatics tools and closer integration of digital and biological technologies. - The report defines bioconvergence as the merger of biology with engineering, data science and advanced technology to support innovation in healthcare and life sciences. - The report says the field is aimed at faster, more affordable and more effective development of new therapies, devices and platforms. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report’s 2026 edition adds market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated graphics and tables. - The report also adds key technologies and future trend analysis. - The company offers a free sample of the report at Download a free sample. - The full report is available at Read the full market report.
Between the lines: - Personalized medicine appears to be the clearest near-term demand driver because it links bioconvergence to treatments tailored to a patient’s genetics, environment and lifestyle. - The report points to a market that is shifting from research-led experimentation toward commercial platforms built around AI, diagnostics and precision medicine. - FDA approvals cited in the release suggest the personalized medicine category is already gaining regulatory traction. - The release says the Personalized Medicine Coalition reported 26 FDA-approved personalized medicines in 2023, up from 12 in 2022. - North America’s lead suggests the market still depends on mature research infrastructure, while Asia-Pacific’s growth points to where new investment may cluster next.
What's next: - Market growth is expected to continue through 2030 if personalized medicine, AI applications and bioengineering investment keep expanding. - The report’s regional outlook suggests Asia-Pacific could narrow the gap with North America as healthcare infrastructure and biotech investment improve. - More cross-industry partnerships are likely as companies combine biological research with digital and engineering tools.
The bottom line: - Bioconvergence is shifting from a niche concept to a fast-growing market tied to the next wave of healthcare innovation.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
STEM News Today
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.